2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-175268
    PXR ligand-Linker Conjugate 1
    PXR ligand-Linker Conjugate 1 is a conjugate of PXR ligand and linker, which can be used to synthesize PROTAC MI1013 (HY-175266).
    PXR ligand-Linker Conjugate 1
  • HY-175303
    Xanthine oxidase-IN-17 185522-92-3 98%
    Xanthine oxidase-IN-17 is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 298 nM and a Ki of 167 nM. Xanthine oxidase-IN-17 decreases the formation of O₂⁻ radical by inhibiting the catalytic activity of XOD to diminish the production of uric acid. Xanthine oxidase-IN-17 shows no cytotoxicity in AML-12 hepatocytes, while suppressing uric acid production. Xanthine oxidase-IN-17 can be used for the studies of hyperuricemia and subsequently to gout.
    Xanthine oxidase-IN-17
  • HY-175315
    Carbonic anhydrase-IN-34
    Carbonic anhydrase-IN-34 is a carbonic anhydrases (CAs) inhibitor (compound 9d) with IC50s of 1.01 μM against hCA-II, 0.21 μM against hCA-IX and 0.88 μM against hCA-XII. Carbonic anhydrase-IN-34 has potential applications in the research of several disorders, including epilepsy, glaucoma, obesity, and cancer.
    Carbonic anhydrase-IN-34
  • HY-175331
    ALR2-IN-7 59935-47-6 99.94%
    ALR2-IN-7 (Compound 5a) is a highly potent and selective aldose reductase (ALR2/AKR1B1) inhibitor (Ki=8.71 nM). ALR2-IN-7 is promising for research of diabetic complications (e.g., retinopathy, nephropathy) and cancers.
    ALR2-IN-7
  • HY-17538A
    ZLN005 hydrochloride 2319647-97-5
    ZLN005 (hydrochloride) is a peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1α) activator. ZLN005 (hydrochloride) can stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, improve glucose utilization and fatty acid oxidation. ZLN005 (hydrochloride) can increase the transcription of PGC-1α and downstream genes in skeletal muscle of diabetic db/db mice, increase fat oxidation and improve glucose tolerance, pyruvate tolerance and insulin sensitivity.
    ZLN005 hydrochloride
  • HY-175392
    PROTAC sEH-degrader-3 3093413-94-3 98%
    PROTAC sEH-degrader-3 (Compound 1a) is a targeted sEH PROTAC degrader that can selectively degrade sEH in the cytosol without affecting sEH in peroxisomes. PROTAC sEH-degrader-3 degrades sEH through a CRBN-dependent lysosomal pathway rather than the proteasome, with an IC50 of 0.8 nM against hsEH. PROTAC sEH-degrader-3 can inhibit endoplasmic reticulum stress and can be used in the research of inflammation, metabolic diseases, and other diseases related to endoplasmic reticulum stress.
    PROTAC sEH-degrader-3
  • HY-175394
    β-Hydroxybutyrate methionine 98%
    β-Hydroxybutyrate methionine is a conjugate of β-Hydroxybutyrate and methionine. β-Hydroxybutyrate methionine can be used in obesity research.
    β-Hydroxybutyrate methionine
  • HY-175418
    LaKe
    LaKe is an orally active simple ester prodrug. LaKe is promising for research of metabolic syndrome and neurodegenerative diseases.
    LaKe
  • HY-175420
    K-757 2696409-13-7 98%
    K-757 is a GPR40 agonist with an EC50 of 2.1 ± 0.2 nM for human GPR40. K-757 exhibits a half-life of 1-11 h in Preclinical Species. K-757 stimulates GLP-1 secretion and has potential applications in bariatric research.
    K-757
  • HY-175422
    K-833 2639936-77-7 98%
    K-833 is a GPR119 agonist with EC50 values of 39.8 nM (human), 100nM (mouse), 75.4 nM (rat) and 12.6 nM (dog). K-833 demonstrates a modest increase in GLP-1 secretion and leads to a synergistic increase in GLP-1 levels when combined with AM-5262 (HY-16619) in acute gut peptide secretion assays in mice. K-833 can be used in studies on weight loss.
    K-833
  • HY-175464
    NLRP3-IN-82 3091347-92-8
    NLRP3-IN-82 (Compound 2b) is a NLRP3IC50< 5 nM). NLRP3-IN-82 can be used for neurological diseases like Alzheimer's disease, inflammatory diseases like inflammatory bowel disease and metabolic disorders like obesity research.
    NLRP3-IN-82
  • HY-175480
    RXR agonist 2
    RXR agonist 2 (Compound 22) is a highly selective retinoid X receptor (RXR) agonist (EC50=0.039 μM). RXR agonist 2 is promising for research of metabolic syndrome and Alzheimer's disease.
    RXR agonist 2
  • HY-175494
    α-Glucosidase-IN-96 98%
    α-Glucosidase-IN-96 (Compounds 7b) is a potent α-Glucosidase inhibitor with IC50 values of 9.23 ~ 9.61 μM. α-Glucosidase-IN-96 can be used in diabetes research.
    α-Glucosidase-IN-96
  • HY-175605
    α-Amylase/α-Glucosidase-IN-21 98%
    α-Amylase/α-Glucosidase-IN-21 (Compound 4) is a dual-functional inhibitor of α-Glucosidase and α-Amylase with IC50s of 0.27 and  0.19 µg/mL for α-Glucosidase and α-Amylase, respectively. α-Amylase/α-Glucosidase-IN-21 has an antidiabetic activity.α-Amylase/α-Glucosidase-IN-21 can be used for diabetes mellitus research.
    α-Amylase/α-Glucosidase-IN-21
  • HY-175639
    ALR2-IN-8
    ALR2-IN-8 is a potent aldose reductase (ALR2/AKR1B1) inhibitor with a KI of 7.34 nM. ALR2-IN-8 has extremely low toxicity to normal cells and has a weak direct killing effect on cancer cells. ALR2-IN-8 can used for the studies of diabetic and inflammation-linked disorders.
    ALR2-IN-8
  • HY-175645
    NLRP3/URAT1-IN-1 2994637-53-3 98%
    NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC50 = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC50 of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia.
    NLRP3/URAT1-IN-1
  • HY-175663
    EYE-002
    EYE-002 is a RPE65 inhibitor with an IC50 of 69 nM. EYE-002 promotes recovery of scotopic ERG a-/b-wave amplitudes. EYE-002 regulates the visual cycle in mice by reducing 11-cis-retinal (11cRAL) (HY-116711) synthesis and increasing all-trans-retinyl esters (atREs). EYE-002 exerts protective effects against photic retinal damage in mice. EYE-002 can be used for the study of visual cycle-associated retinopathies, such as Stargardt disease type 1 (STGD1).
    EYE-002
  • HY-175664
    EYE-003
    EYE-003 is an orally active RPE65 inhibitor with an IC50 of 102 nM. EYE-003 regulates the visual cycle in mice by reducing 11-cis-retinal (11cRAL) (HY-116711) synthesis and increasing all-trans-retinyl esters (atREs). EYE-003 suppresses scotopic ERG b-wave amplitude and exerts protective effects against retinal degeneration in Abca4⁻/⁻ Rdh8⁻/⁻ mice (a STGD1 model) by reducing retinal autofluorescent puncta and preserving outer nuclear layer (ONL) thickness in a dose-dependent manner. EYE-003 can be used for the study of visual cycle-associated retinopathies, such as Stargardt disease type 1 (STGD1).
    EYE-003
  • HY-175669
    ANO1-IN-5 98%
    ANO1-IN-5 is an orally active ANO1 inhibitor with an IC50 of 4.57 μM. J ANO1-IN-5 demonstrates 118-, 642-, and 10000-fold selectivity over α1A-,α1B-, andα1D-AR, respectively. ANO1-IN-5 exhibits significant inhibitory effects on osteoclast differentiation and function. ANO1-IN-5 can used for the study of osteoporosis.
    ANO1-IN-5
  • HY-175676
    THR-β agonist 10
    THR-β agonist 10 is an orally active and selective THR-β agonist, with an EC50 of 11 nM. THR-β agonist 10 significantly reduces ALT (Alanine Aminotransferase), TC (Total Cholesterol), and LDL-C (Low-Density Lipoprotein Cholesterol) levels, and improves steatosis, ballooning, inflammation and fibrosis in the metabolic dysfunction-associated steatohepatitis (MASH) mouse model. THR-β agonist 10 can be used for the study of MASH.
    THR-β agonist 10
Cat. No. Product Name / Synonyms Application Reactivity